Frontiers in Pharmacology (Oct 2024)

Evaluation of the role of metabolizing enzymes and transporter variants in ezetimibe pharmacokinetics

  • Eva González-Iglesias,
  • Eva González-Iglesias,
  • Dolores Ochoa,
  • Dolores Ochoa,
  • Marcos Navares-Gómez,
  • Pablo Zubiaur,
  • Pablo Zubiaur,
  • Marina Aldama,
  • Tamara de la Torre,
  • Marta de los Ríos-Rodríguez,
  • Paula Soria-Chacartegui,
  • Paula Soria-Chacartegui,
  • Andrea Rodríguez-Lopez,
  • Andrea Rodríguez-Lopez,
  • Francisco Abad-Santos,
  • Francisco Abad-Santos,
  • Francisco Abad-Santos,
  • Jesús Novalbos

DOI
https://doi.org/10.3389/fphar.2024.1414059
Journal volume & issue
Vol. 15

Abstract

Read online

IntroductionEzetimibe inhibits cholesterol uptake by modulation of intestinal sterol absorption. Currently, although some studies have shown alterations in ezetimibe levels caused by alterations in the ABCG5, ABCG8, NPC1L1 or UGT1A1 genes, there are no pharmacogenetic guidelines to confirm these biomarkers. The aim of this work was to evaluate the effect of 49 variants in 22 pharmacogenes related to metabolism and transport.MethodsA total of 96 healthy volunteers from four bioequivalence clinical trials of ezetimibe as monotherapy or in combination with simvastatin were studied. Blood samples were extracted for unconjugated ezetimibe plasma quantification and genotyping.Results and DiscussionNo association of metabolizing enzyme variants with ezetimibe pharmacokinetic parameters was found. The results show some trends in the univariate analysis for ABCB1 rs2032582 or ABCC2 rs2273697 and Cmax (p univariate (puv) = 0.056 and 0.087, respectively), which finally reach significance in the multivariate analysis (p multivariate (pmv) = 0.049 and 0.048, respectively). Nevertheless, these results need to be validated in future studies.

Keywords